Clinical Trials on ERK Mutation in Canada

Total 106 results

  • AstraZeneca
    Active, not recruiting
    Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
    Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive
    United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
  • 23andMe, Inc.
    Active, not recruiting
    A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
    Clear Cell Renal Cell Carcinoma | Fallopian Tube Cancer | Solid Tumor | Neuroendocrine Tumors | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Extensive-stage Small-cell Lung Cancer | MSI-H Cancer | Cancer With A High Tumor Mutational Burden
    United States, Canada
  • Epizyme, Inc.
    Completed
    A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
    Synovial Sarcoma | Epithelioid Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumors (MRT) | Rhabdoid Tumors of the Kidney (RTK) | Atypical Teratoid Rhabdoid Tumors (ATRT) | Selected Tumors With Rhabdoid Features | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Poorly Differentiated... and other conditions
    France, United States, Australia, Taiwan, Belgium, United Kingdom, Canada, Germany, Italy
  • Novartis Pharmaceuticals
    Completed
    Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
    Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...
    Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
  • Apollomics Inc.
    Recruiting
    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)
    Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping
    United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
  • Medicenna Therapeutics, Inc.
    Merck Sharp & Dohme LLC
    Recruiting
    A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
    Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions
    United States, Australia, Korea, Republic of, Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe